Upgrade to SI Premium - Free Trial

Jefferies Reiterates Buy Rating on Biogen (BIIB) following FDA approval of HD Spinraza for SMA

March 30, 2026 9:24 AM
Jefferies analyst Andrew Tsai reiterated a Buy rating and $210.00 price target on Biogen (NASDAQ: BIIB)The analyst commented, "As we ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments